Quanterix Corp
NASDAQ:QTRX
Quanterix Corp
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.
Revenue Growth: Quanterix reported Q3 revenue of $40.2 million, up 12% year-over-year, in line with expectations despite industry headwinds.
Integration Progress: The Akoya acquisition is ahead of schedule, with $67 million of $85 million in targeted synergies already realized, consolidating operations and teams.
Segment Trends: Simoa revenues declined 36% year-over-year, while Spatial revenues fell 9%; weakness attributed to smaller project sizes in academic and pharma markets.
Guidance Maintained: Full-year 2025 revenue guidance of $130–135 million and cash usage guidance of $34–38 million were reiterated, with $120 million in year-end cash expected.
Diagnostics Momentum: Diagnostics revenue reached $2.4 million in Q3, with LucentAD test pending final pricing approval and new partner growth in Asia.
Profitability Path: Cost synergies and disciplined cash management are expected to drive cash flow breakeven by 2026, with no debt on the balance sheet.
R&D Investment: Year-to-date R&D investment stands at about $27 million, just under 30% of revenue, supporting next-gen platforms and assay expansion.
